Glaukos Awaits iStent Approval, And New Randomized Trial Requirement
This article was originally published in The Gray Sheet
Executive Summary
Glaukos will likely have to conduct a new, five-year prospective randomized post-market study for its iStent glaucoma device if FDA approves the product's PMA